The infusion was safe without evidence of off-tumor toxicity or CRS and no cross-reactivity to wild type EGFR, except one patient developed non-convulsive status epilepticus 9 days after infusion, which was resolved with standard treatment and anti-cytokine therapy. This evidence concerns the gene EGFR and neoplasm.